These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
144 related articles for article (PubMed ID: 39153094)
21. Dutasteride and bicalutamide in patients with hormone-refractory prostate cancer: the Therapy Assessed by Rising PSA (TARP) study rationale and design. Sartor O; Gomella LG; Gagnier P; Melich K; Dann R Can J Urol; 2009 Oct; 16(5):4806-12. PubMed ID: 19796455 [TBL] [Abstract][Full Text] [Related]
22. The long-term results with delayed-combined androgen blockade therapy in local or locally advanced prostate cancer. Soga N; Hori Y; Ogura Y; Hayashi N; Sugimura Y Jpn J Clin Oncol; 2012 Jun; 42(6):534-40. PubMed ID: 22438406 [TBL] [Abstract][Full Text] [Related]
23. Phase I trial of tremelimumab in combination with short-term androgen deprivation in patients with PSA-recurrent prostate cancer. McNeel DG; Smith HA; Eickhoff JC; Lang JM; Staab MJ; Wilding G; Liu G Cancer Immunol Immunother; 2012 Jul; 61(7):1137-47. PubMed ID: 22210552 [TBL] [Abstract][Full Text] [Related]
24. Prostate-specific antigen progression predicts overall survival in patients with metastatic prostate cancer: data from Southwest Oncology Group Trials 9346 (Intergroup Study 0162) and 9916. Hussain M; Goldman B; Tangen C; Higano CS; Petrylak DP; Wilding G; Akdas AM; Small EJ; Donnelly BJ; Sundram SK; Burch PA; Dipaola RS; Crawford ED J Clin Oncol; 2009 May; 27(15):2450-6. PubMed ID: 19380444 [TBL] [Abstract][Full Text] [Related]
25. Third-line hormonal therapy to treat prostate cancer relapse after initial and second-line hormonal therapy: report of 52 cases and literature review. Matsumoto K; Hagiwara M; Hayakawa N; Tanaka N; Ito Y; Maeda T; Ninomiya A; Nagata H; Nakamura S Asian Pac J Cancer Prev; 2014; 15(8):3645-9. PubMed ID: 24870772 [TBL] [Abstract][Full Text] [Related]
26. Bone Pain and Survival Among Patients With Metastatic, Hormone-Sensitive Prostate Cancer: A Secondary Analysis of the SWOG-1216 Trial. Gebrael G; Jo Y; Swami U; Plets M; Hage Chehade C; Narang A; Gupta S; Myint ZW; Sayegh N; Tangen CM; Hussain M; Dorff T; Lara PN; Lerner SP; Thompson I; Agarwal N JAMA Netw Open; 2024 Jul; 7(7):e2419966. PubMed ID: 38980676 [TBL] [Abstract][Full Text] [Related]
28. Effect of Adding Docetaxel to Androgen-Deprivation Therapy in Patients With High-Risk Prostate Cancer With Rising Prostate-Specific Antigen Levels After Primary Local Therapy: A Randomized Clinical Trial. Oudard S; Latorzeff I; Caty A; Miglianico L; Sevin E; Hardy-Bessard AC; Delva R; Rolland F; Mouret L; Priou F; Beuzeboc P; Gravis G; Linassier C; Gomez P; Voog E; Muracciole X; Abraham C; Banu E; Ferrero JM; Ravaud A; Krakowski I; Lagrange JL; Deplanque G; Zylberait D; Bozec L; Houede N; Culine S; Elaidi R JAMA Oncol; 2019 May; 5(5):623-632. PubMed ID: 30703190 [TBL] [Abstract][Full Text] [Related]
29. Diethylstilboestrol versus bicalutamide in hormone refractory prostate carcinoma: a prospective randomized trial. Manikandan R; Srirangam SJ; Pearson E; Brown SC; O'Reilly P; Collins GN Urol Int; 2005; 75(3):217-21. PubMed ID: 16215308 [TBL] [Abstract][Full Text] [Related]
30. A randomized phase II trial on the addition of dutasteride to combined androgen blockade therapy versus combined androgen blockade therapy alone in patients with advanced or metastatic salivary duct carcinoma - the DUCT study protocol. Weijers JAM; Verhaegh GW; Lassche G; van Engen-van Grunsven ACH; Driessen CML; van Erp NP; Jonker MA; Schalken JA; van Herpen CML BMC Cancer; 2024 Sep; 24(1):1174. PubMed ID: 39304797 [TBL] [Abstract][Full Text] [Related]
31. Treatment of localized prostate cancer with intermittent triple androgen blockade: preliminary results in 110 consecutive patients. Leibowitz RL; Tucker SJ Oncologist; 2001; 6(2):177-82. PubMed ID: 11306729 [TBL] [Abstract][Full Text] [Related]
32. A phase II trial of androgen deprivation therapy (ADT) plus chemotherapy as initial treatment for local failures or advanced prostate cancer. Amato R; Stepankiw M; Gonzales P Cancer Chemother Pharmacol; 2013 Jun; 71(6):1629-34. PubMed ID: 23604530 [TBL] [Abstract][Full Text] [Related]
33. Complete remission of metastatic carcinoma of the prostate with bicalutamide withdrawal. Kundranda MN; Muslimani A; Daw HA; Spiro TP Clin Genitourin Cancer; 2007 Sep; 5(6):401-2. PubMed ID: 17956714 [TBL] [Abstract][Full Text] [Related]
34. Significance of baseline bone markers on disease progression and survival in hormone-sensitive prostate cancer with bone metastasis. Nozawa M; Hara I; Matsuyama H; Iki M; Nagao K; Nishioka T; Komura T; Esa A; Uejima S; Imanishi M; Uekado Y; Ogawa T; Kajikawa H; Uemura H World J Urol; 2015 Sep; 33(9):1263-8. PubMed ID: 25354720 [TBL] [Abstract][Full Text] [Related]
35. Usefulness of combined androgen blockade therapy with gonadotropin-releasing hormone antagonist for bone metastatic prostate cancer with pretreatment prostate-specific antigen level ≥ 50 ng/mL. Kashiwabara T; Suda S BMC Cancer; 2018 May; 18(1):619. PubMed ID: 29855278 [TBL] [Abstract][Full Text] [Related]
36. Enzalutamide versus flutamide for castration-resistant prostate cancer after combined androgen blockade therapy with bicalutamide: the OCUU-CRPC study. Iguchi T; Tamada S; Kato M; Yasuda S; Machida Y; Ohmachi T; Ishii K; Iwata H; Yamamoto S; Kanamaru T; Morimoto K; Hase T; Tashiro K; Harimoto K; Deguchi T; Adachi T; Iwamoto K; Takegaki Y; Nakatani T Int J Clin Oncol; 2020 Mar; 25(3):486-494. PubMed ID: 31564004 [TBL] [Abstract][Full Text] [Related]
37. Intermittent versus continuous androgen deprivation in prostate cancer. Hussain M; Tangen CM; Berry DL; Higano CS; Crawford ED; Liu G; Wilding G; Prescott S; Kanaga Sundaram S; Small EJ; Dawson NA; Donnelly BJ; Venner PM; Vaishampayan UN; Schellhammer PF; Quinn DI; Raghavan D; Ely B; Moinpour CM; Vogelzang NJ; Thompson IM N Engl J Med; 2013 Apr; 368(14):1314-25. PubMed ID: 23550669 [TBL] [Abstract][Full Text] [Related]
38. Bicalutamide 150 mg as secondary hormonal therapy for castration-resistant prostate cancer. Qian SB; Shen HB; Cao QF; Zhang L; Chen YF; Qi J Int Urol Nephrol; 2015 Mar; 47(3):479-84. PubMed ID: 25665794 [TBL] [Abstract][Full Text] [Related]
39. Survival outcomes of real world patients with metastatic hormone-sensitive prostate cancer who do not achieve optimal PSA response with intensified androgen deprivation therapy with docetaxel or androgen receptor pathway inhibitors. Gebrael G; Sayegh N; Thomas VM; Chigarira B; Tripathi N; Jo YJ; Li H; Sahu KK; Srivastava A; McFarland T; Maughan BL; Swami U; Agarwal N Prostate Cancer Prostatic Dis; 2024 Jun; 27(2):279-282. PubMed ID: 37460732 [TBL] [Abstract][Full Text] [Related]
40. Survival benefit of early androgen receptor inhibitor therapy in locally advanced prostate cancer: long-term follow-up of the SPCG-6 study. Thomsen FB; Brasso K; Christensen IJ; Johansson JE; Angelsen A; Tammela TL; Iversen P; Eur J Cancer; 2015 Jul; 51(10):1283-92. PubMed ID: 25892647 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]